<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: Aberrant promoter methylation targets CpG islands causing gene silencing </plain></SENT>
<SENT sid="1" pm="."><plain>We explored aberrant promoter methylation of genes potentially involved in B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> and encoding proteins implicated in DNA repair (O6-methylguanine-DNA methyltransferase, MGMT), detoxification of environmental <z:chebi fb="0" ids="35703">xenobiotics</z:chebi> (<z:chebi fb="0" ids="16856">glutathione</z:chebi> S-transferase P1, GSTP1), <z:mpath ids='MPATH_3'>apoptosis</z:mpath> regulation (<z:hpo ids='HP_0011420'>death</z:hpo> associated protein kinase, DAP-k and caspase 8, CASP8) and cell cycle control (p73) </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN AND METHODS: Three hundred and seventeen B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> were investigated by methylation-specific polymerase chain reaction (MSP) of MGMT, GSTP1, DAP-k, CASP8 and p73 genes </plain></SENT>
<SENT sid="3" pm="."><plain>In selected cases, MSP results were matched to protein expression studies by immunohistochemistry or Western blotting </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: DAP-k promoter methylation occurred at highest frequency in follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (85.0%) and MALT-<z:hpo ids='HP_0002665'>lymphoma</z:hpo> (72.2%) </plain></SENT>
<SENT sid="5" pm="."><plain>MGMT methylation targeted both precursor B-cell <z:hpo ids='HP_0002664'>neoplasia</z:hpo> (23.8%) and mature B-cell <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> (27.6%) </plain></SENT>
<SENT sid="6" pm="."><plain>GSTP1 methylation was commonest in hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo> (75.0%), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (55.5%), Burkitt s <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (52.0%), and MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (50.0%) </plain></SENT>
<SENT sid="7" pm="."><plain>Methylation of p73 and CASP8 was rare or absent </plain></SENT>
<SENT sid="8" pm="."><plain>DAP-k and MGMT methylation caused absent protein expression </plain></SENT>
<SENT sid="9" pm="."><plain>INTERPRETATION AND CONCLUSIONS: Methylation of MGMT, DAP-k and GSTP1 represents a major pathogenetic event in several B-cell <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>In follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, frequent inactivation of the <z:mpath ids='MPATH_3'>apoptosis</z:mpath> extrinsic pathway through DAP-k methylation may reinforce the survival advantage already conferred by deregulation of the intrinsic apoptotic pathway </plain></SENT>
<SENT sid="11" pm="."><plain>Inactivation of GSTP1 in gastric MALT <z:hpo ids='HP_0002665'>lymphoma</z:hpo> represents an additional mechanism favoring accumulation of reactive oxygen species and <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">lymphomagenesis</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Finally, the frequency of GSTP1 aberrant methylation in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> prompts studies aimed at verifying the prognostic impact of this epigenetic lesion in these <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
</text></document>